Ascletis Pharma, Inc. (HK:1672) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Ascletis Pharma Inc. revealed promising Phase I study results for its innovative weight loss drug, ASC47, showcasing significant fat reduction and muscle preservation compared to existing treatments. The study in Australia highlighted ASC47’s potential for once-monthly administration due to its 21-day half-life and impressive tolerance profile with minimal adverse effects. These findings position ASC47 as a compelling candidate in the obesity treatment market, with further studies underway.
For further insights into HK:1672 stock, check out TipRanks’ Stock Analysis page.